Age-related cognitive decline (ARCD) is a complex convergent phenotype that prominently involves impaired executive function (EF) likely through disruption of the dorsolateral prefrontal cortex (PFC) circuit;despite much speculation, the cellular and molecular mechanisms that underlie this presumed disruption have not been demonstrated in humans. Cognitive impairment (Cl) or dementia (D) is highly prevalent among patients with Parkinson's disease (PD) but remains an incompletely understood non- motor complication of this devastating illness. Indeed, many patients with PD have neuropsychologically determined "Cl, no dementia" (PD-CIND) at the time of initial diagnosis. Like ARCD, patients with PD- CIND or PD-D display prominently impairment of EF;however, also like ARCD, the cellular and molecular bases are not clear. We hypothesize that selective regional- and neurotransmitter-specific degeneration in PFC or anterior neostriatum contributes significantly to impaired EF in ARCD, PD-CI, and PD-D. In Project 2 we will test our hypothesis through the following Specific Aims: (i) determine the magnitude and regional distribution of dopamine (DA), norepinephrine (NE), and serotonin (5HT) degeneration in neocortex and neostriatum, and their associations with cognitive function test results, from aged individuals without PD or dementia but varying levels of ARCD, aged individuals with pathologic changes of PD but not a clinical diagnosis of PD and varying levels of Cl, and patients with closely related neurodegenerative diseases, (ii) determine the magnitude, regional distribution, and associations with cognitive test results of neostriatal medium spiny neuron spinodendritic degeneration in the same people whose tissue was investigated in Aim 1, and (iii) determine if selective loss of DA neurotransmission without neurodegeneration leads to regionally restricted spinodendritic degeneration in mice from Project 1. Completion of these Specific Aims will provide the first integrated clinical, behavioral, morphometric, and neurochemical analysis of PFC and neostriatum in ARCD and PD with and without cognitive impairment, as well as in novel transgenic mice. This project is responsive to several points in the NIH Blueprint: it is a direct response to the therapeutic imperative for PD, it is highly translational as it will inform critically neurolmaging and therapeutic efforts, and it draws on existing NIH funded resources.

Public Health Relevance

This project will provide rationale for new evidence-based interventions for cognitive impairment in PD beyond DA replacement strategies, including enhancing synaptic levels of other neurotransmitters, preventing death of selected neuron populations, or ameliorating the consequences of cell death.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS062684-05
Application #
8535837
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
5
Fiscal Year
2013
Total Cost
$178,840
Indirect Cost
$54,213
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Chahine, Lama M; Stern, Matthew B; Chen-Plotkin, Alice (2014) Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord 20 Suppl 1:S99-103
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12
Shi, Min; Liu, Changqin; Cook, Travis J et al. (2014) Plasma exosomal ?-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 128:639-50
Burdick, Daniel J; Cholerton, Brenna; Watson, G S et al. (2014) People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord 29:1258-64
Gallardo, Christian M; Darvas, Martin; Oviatt, Mia et al. (2014) Dopamine receptor 1 neurons in the dorsal striatum regulate food anticipatory circadian activity rhythms in mice. Elife 3:e03781
Halliday, Glenda M; Leverenz, James B; Schneider, Jay S et al. (2014) The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 29:634-50
Darvas, Martin; Henschen, Charles W; Palmiter, Richard D (2014) Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease. Neurobiol Dis 65:112-23
Cohen, Rajal G; Klein, Krystal A; Nomura, Mariko et al. (2014) Inhibition, executive function, and freezing of gait. J Parkinsons Dis 4:111-22
Nuytemans, Karen; Inchausti, Vanessa; Beecham, Gary W et al. (2014) Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. Mov Disord 29:827-30
Stewart, Tessandra; Sui, Yu-Ting; Gonzalez-Cuyar, Luis F et al. (2014) Cheek cell-derived *-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiol Aging 35:418-20

Showing the most recent 10 out of 81 publications